Inhibition of autolysosomes by repurposing drugs as a promising therapeutic strategy for the treatment of cancers

Autophagy process coordinates lysosomal destruction of cytoplasmic materials including damaged organelles and proteins. The double-membranous ‘autophagosome’ selectively sequesters the cytosolic components, followed by ‘autolysosome’ formation for degradation. By recycling energy, autophagy preserve...

Full description

Bibliographic Details
Main Author: Abdul Alim Al-Bari
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:All Life
Subjects:
Online Access:http://dx.doi.org/10.1080/26895293.2022.2078894
_version_ 1797236901904646144
author Abdul Alim Al-Bari
author_facet Abdul Alim Al-Bari
author_sort Abdul Alim Al-Bari
collection DOAJ
description Autophagy process coordinates lysosomal destruction of cytoplasmic materials including damaged organelles and proteins. The double-membranous ‘autophagosome’ selectively sequesters the cytosolic components, followed by ‘autolysosome’ formation for degradation. By recycling energy, autophagy preserves intracellular homeostasis. Autophagy also acts a crucial function in various cellular events including cell survival and death in response to stressed conditions. Thus, any dysfunction in autophagy causes a wide variety of pathologies including cancers. Multiple lines of evidence have decorated the importance of autophagy for the regulation of cancer development. Aberrant autophagy can govern healthy normal cells to endure the transformation of malignant cells. By comparison, cancer cells are apt to control autophagy to bloom it and to repel therapeutic challenges. Hence, the modulation of autolysosomes can assassinate malignant cells or sharpen them for therapy. Most current research is trying to manipulate autophagy appropriately for cancer therapies and a wide variety of medical objectives are turning forward to inhibit the acidification of lysosomes and autolysosomes with repurposing drugs. This review explores the lysosomotropic agents be utilized to treat cancers through their inhibiting roles in the acidification system and discuss the preclinical and clinical clues for hints the next generation of pharmacological agents for the treatment of cancers.
first_indexed 2024-03-08T16:58:29Z
format Article
id doaj.art-0601bf7aa58144d389d28681125f01c0
institution Directory Open Access Journal
issn 2689-5307
language English
last_indexed 2024-04-24T17:11:13Z
publishDate 2022-12-01
publisher Taylor & Francis Group
record_format Article
series All Life
spelling doaj.art-0601bf7aa58144d389d28681125f01c02024-03-28T09:48:50ZengTaylor & Francis GroupAll Life2689-53072022-12-0115156860110.1080/26895293.2022.20788942078894Inhibition of autolysosomes by repurposing drugs as a promising therapeutic strategy for the treatment of cancersAbdul Alim Al-Bari0University of RajshahiAutophagy process coordinates lysosomal destruction of cytoplasmic materials including damaged organelles and proteins. The double-membranous ‘autophagosome’ selectively sequesters the cytosolic components, followed by ‘autolysosome’ formation for degradation. By recycling energy, autophagy preserves intracellular homeostasis. Autophagy also acts a crucial function in various cellular events including cell survival and death in response to stressed conditions. Thus, any dysfunction in autophagy causes a wide variety of pathologies including cancers. Multiple lines of evidence have decorated the importance of autophagy for the regulation of cancer development. Aberrant autophagy can govern healthy normal cells to endure the transformation of malignant cells. By comparison, cancer cells are apt to control autophagy to bloom it and to repel therapeutic challenges. Hence, the modulation of autolysosomes can assassinate malignant cells or sharpen them for therapy. Most current research is trying to manipulate autophagy appropriately for cancer therapies and a wide variety of medical objectives are turning forward to inhibit the acidification of lysosomes and autolysosomes with repurposing drugs. This review explores the lysosomotropic agents be utilized to treat cancers through their inhibiting roles in the acidification system and discuss the preclinical and clinical clues for hints the next generation of pharmacological agents for the treatment of cancers.http://dx.doi.org/10.1080/26895293.2022.2078894autolysosomeautophagy-lysosomal pathwaylysosomal functiondrug repurposingchloroquine analoguecancer therapy
spellingShingle Abdul Alim Al-Bari
Inhibition of autolysosomes by repurposing drugs as a promising therapeutic strategy for the treatment of cancers
All Life
autolysosome
autophagy-lysosomal pathway
lysosomal function
drug repurposing
chloroquine analogue
cancer therapy
title Inhibition of autolysosomes by repurposing drugs as a promising therapeutic strategy for the treatment of cancers
title_full Inhibition of autolysosomes by repurposing drugs as a promising therapeutic strategy for the treatment of cancers
title_fullStr Inhibition of autolysosomes by repurposing drugs as a promising therapeutic strategy for the treatment of cancers
title_full_unstemmed Inhibition of autolysosomes by repurposing drugs as a promising therapeutic strategy for the treatment of cancers
title_short Inhibition of autolysosomes by repurposing drugs as a promising therapeutic strategy for the treatment of cancers
title_sort inhibition of autolysosomes by repurposing drugs as a promising therapeutic strategy for the treatment of cancers
topic autolysosome
autophagy-lysosomal pathway
lysosomal function
drug repurposing
chloroquine analogue
cancer therapy
url http://dx.doi.org/10.1080/26895293.2022.2078894
work_keys_str_mv AT abdulalimalbari inhibitionofautolysosomesbyrepurposingdrugsasapromisingtherapeuticstrategyforthetreatmentofcancers